**
In a striking revelation, internal records have surfaced showing that top officials from the Environmental Protection Agency (EPA) met with Bayer CEO Bill Anderson last year to discuss the company’s ongoing legal battles surrounding its glyphosate herbicides. This meeting took place just months before the Trump administration took significant steps that would bolster Bayer’s position in the Supreme Court, raising serious concerns about the intertwining of corporate interests and regulatory action.
Corporate Lobbying Meets Regulatory Oversight
On 17 June, Anderson, accompanied by two other Bayer executives, engaged in discussions at the EPA. The agenda, according to a planning email obtained through a Freedom of Information Act request, included “litigation” and “supreme court action” related to glyphosate, particularly the popular herbicide Roundup. This meeting came at a critical time for Bayer, as the company faced an avalanche of lawsuits from thousands of individuals claiming that exposure to its glyphosate products had caused them cancer.
The lawsuits allege that Bayer failed to adequately warn consumers about the cancer risks associated with glyphosate, a claim supported by numerous studies over the years. As Bayer sought to mitigate the financial fallout from these legal challenges, the company’s strategy hinged on persuading the Supreme Court to accept its assertion that it should not be held liable for any cancer warnings if the EPA does not mandate them.
A Pattern of Political Support
Since the meeting, the Trump administration has taken several actions that appear to favour Bayer. In a 1 December filing, Solicitor General D John Sauer—appointed by Trump—urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to do, with a hearing set for 27 April. Additionally, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, effectively providing “immunity” to manufacturers like Bayer.
Bayer defended the meeting as a routine part of the regulatory process and insisted that it has been forthcoming about its stance on glyphosate litigation. However, critics argue that such meetings reflect a troubling trend where corporate executives have privileged access to regulatory bodies, enabling them to influence the very policies that could impact public health.
Voices of Dissent
Environmental advocates have voiced alarm over the implications of these meetings. Nathan Donley, an environmental health science director at the Center for Biological Diversity, remarked, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” This sentiment echoes a broader concern regarding the influence of corporate lobbying on regulatory decisions, particularly in industries that significantly affect public health.
Legal experts have also raised red flags. Whitney Di Bona, a consumer safety advocate, questioned whether the EPA extends the same opportunity for dialogue to those negatively impacted by glyphosate. “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” she said.
Naomi Oreskes, a Harvard professor, noted that such high-level meetings between corporate leaders and government officials are indicative of a systemic issue where industry interests overshadow those of everyday citizens.
The Fight for Transparency
Zen Honeycutt, founder of Moms Across America, expressed her disappointment but not surprise over the findings. “Coercion by chemical companies on our regulatory agencies is nothing new,” she commented. Her organisation has repeatedly called for action against harmful pesticides, highlighting the disparity between corporate influence and grassroots advocacy.
Bayer’s close relationship with the Trump administration raises critical questions about the integrity of regulatory processes. The access and influence that corporate leaders enjoy can overshadow the voices of those affected by their products, highlighting the urgent need for greater transparency and accountability in environmental regulation.
Why it Matters
The implications of this story are profound. The potential collusion between corporations and government agencies not only endangers public health but also erodes trust in regulatory frameworks meant to protect citizens. As the legal battles over glyphosate continue, the spotlight remains on the critical intersection of corporate power and governmental responsibility. To ensure the safety of our communities, it is imperative that the voices of those impacted by environmental hazards are heard, and that regulatory bodies operate with integrity and transparency free from corporate influence.
